Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887214 | 0.95 | ALDH1A1 (0.57) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL14946542 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL18073594 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12943189 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12769207 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12957994 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL11913766 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12841598 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12769198 | 0.91 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL12957786 | 0.91 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218614-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218614-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | LIPA, PHOSPHO1, SGMS1 | ALDH1A1 4705/4885CNR1 4044/4885CNR2 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.